Quantum BioPharma Taps Thermo Fisher's PPD to Run Phase 2 Lucid-MS Trial
QNTM sits 58% above its 52-week low of $2.07.
Summary
Quantum BioPharma signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business (PPD) to implement the Phase 2 trial of Lucid-MS in progressive multiple sclerosis. This follows FDA clearance of the IND in August and moves the program from regulatory approval into operational execution. The partnership with a leading global CRO with deep CNS and MS experience de-risks trial logistics and signals commitment to advancing the asset. No financial terms were disclosed. The trial will evaluate efficacy, safety, and tolerability in a randomized, double-blind, placebo-controlled design. Next milestone is site activation and patient enrollment, though no specific timeline was provided.
At the time of this announcement, QNTM was trading at $3.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.07 to $19.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.